tm logo
RIABNI
Live/Registered
REGISTERED

on 02 Aug 2022

Last Applicant/ Owned by

One Amgen Center Drive

Thousand Oaks

CA

913201799

Serial Number

88182290 filed on 05th Nov 2018

Registration Number

6809212 registered on 02th Aug 2022

in the Principal Register

Correspondent Address

Elsa D. Lemoine

AMGEN INC.

One Amgen Center Drive,

Trademark Operations-MS-28-5A

THOUSAND OAKS, CA 91320-1799

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

RIABNI

Pharmaceutical preparations for treatment of inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granuloRead More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for treatment of inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)


First Use Date in General

04th Jan 2021

First Use Date in Commerce

04th Jan 2021

Mark Details


Serial Number

No 88182290

Mark Type

No Service/Collective Mark

Attorney Docket Number

No TM-1826-US-1

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
02th Aug 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
02th Aug 2022REGISTERED-PRINCIPAL REGISTER
25th Jun 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
24th Jun 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
21st Jun 2022STATEMENT OF USE PROCESSING COMPLETE
16th Jun 2022USE AMENDMENT FILED
16th Jun 2022TEAS STATEMENT OF USE RECEIVED
03rd May 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02th May 2022SOU EXTENSION 5 GRANTED
02th May 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL